Shandon Morrison
Nurse Practitioner · Johnson City, TNNPI 1659817377
Payments from drug & device makers
Across 744 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Johnson & Johnson$663
- Takeda Pharmaceuticals U.S.A., Inc.$632
- Gilead$586
- QOL Medical, LLC$386
- plus $4K from 26 others
What the payments were for
- Food & beverage$11,271100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 195 | $2,875 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 215 | $2,593 |
| Johnson & Johnson | 45 | $663 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $632 |
| Gilead | 36 | $586 |
| QOL Medical, LLC | 16 | $386 |
| Intercept Pharmaceuticals, Inc. | 20 | $362 |
| Daiichi Sankyo Inc. | 17 | $348 |
| Ardelyx, Inc. | 20 | $279 |
| Bristol Myers Squibb | 18 | $271 |
| Lilly USA, LLC | 10 | $268 |
| Sanofi | 16 | $268 |
| Pfizer | 11 | $205 |
| Madrigal Pharmaceuticals | 6 | $194 |
| Ironwood Pharmaceuticals, Inc | 13 | $185 |
| Ipsen Biopharmaceuticals, Inc | 4 | $171 |
| Aimmune Therapeutics, Inc. | 8 | $136 |
| Nestle Healthcare Nutrition Inc. | 8 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $117 |
| Regeneron Healthcare Solutions, Inc. | 6 | $113 |
| Ferring Pharmaceuticals Inc. | 7 | $109 |
| Braintree Laboratories, Inc. | 4 | $78 |
| Celltrion USA Inc. | 4 | $74 |
| Merck | 3 | $54 |
| Evoke Pharma, Inc. | 3 | $49 |
| AstraZeneca | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 5 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $16 |
| Mauna Kea Technologies, Inc. | 1 | $9 |
| Intra-sana Laboratories | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,299 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 14 | $527,729 |
| XifaxanRifaximin | 97 | $313,051 |
| Humira(Cf) PenAdalimumab | 24 | $171,292 |
| LinzessLinaclotide | 146 | $125,914 |
| ZenpepLipase/Protease/Amylase | 27 | $103,929 |
| RelistorMethylnaltrexone Bromide | 16 | $42,425 |
| MotegrityPrucalopride Succinate | 22 | $28,076 |
| CreonLipase/Protease/Amylase | 12 | $17,202 |
| Mesalamine | 16 | $16,234 |
| Lubiprostone | 115 | $13,974 |
| Dexlansoprazole DrDexlansoprazole | 42 | $11,197 |
| MovantikNaloxegol Oxalate | 24 | $11,134 |
| Octreotide Acetate | 33 | $10,670 |
| VoqueznaVonoprazan Fumarate | 14 | $10,167 |
| Omeprazole | 276 | $6,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $663 | $527,72914 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance | $2,593 | $361,375124 claims |
| AbbVieLinzess, Creon | $2,875 | $143,116158 claims |
| Aimmune Therapeutics, Inc.Zenpep | $136 | $103,92927 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $632 | $28,07622 claims |
| Redhill Biopharma Inc.Movantik | $16 | $11,13424 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $22 | $10,16714 claims |
| Braintree Laboratories, Inc.Sutab | $78 | $3,11719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Johnson City
- Abbie HarrisJohnson City$20K
- Brandy StoryJohnson City$18K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.